Pressure Point Inc. Release: How Can Hospital Pharmacies Contribute to Improving Transitional Patient Care Outcomes?
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
July 30, 2013 -- Hospital pharmacies across the US are recognizing the importance of improving patient transitional care in every facet of pharmacy administration. It is no longer a matter of dispensing drug medications, but to match products and services that create solutions, which can lead to improving overall patient satisfaction scores for hospitals. Pharmacies at hospitals are now searching for the best medical approach in order to provide a positive impact in patients’ lives during their hospital stay and after discharge.
An area of pharmaceutical administration that can be improved is antiemetic prophylactic drugs used to control nausea and vomiting symptoms associated with surgery and cancer procedures. Nausea, and to a lesser extent vomiting, continues to impact patients despite the introduction of many new antiemetics. The management issue of nausea following surgery or chemotherapy is still a major concern for hospitals and outpatient centers, since antiemetic drugs do not fully eliminate this debilitating side effect.
Understandably, the unresolved burden of nausea symptoms continues to be a negative influence on patients since this side effect occurrence produces severe quality of life implications, which can lead to a burdensome recovery.
In a collaborative effort to significantly improve transitional patient care associated with antiemetic prophylactic outcomes, a non-pharmacologic (noninvasive) therapy was clinically developed to supplement the primary objectives of antiemetic prophylactic therapy in effectively managing nausea and vomiting. Nausea and vomiting risks are substantially reduced with the adjuvant role of a 72-hour (Pressure Right®) antiemetic device. Its function clearly defines the difference in quality between antiemetics alone and Pressure Right® plus antiemetic therapy.
The proprietary design of the Pressure Right® (P6) wrist stimulation strips uses self-acupressure on the P6 stimulation point to control nausea and vomiting symptoms. The non-pharmacological scientific explanation is that these symptoms result from an imbalance in the flow of energy through the body and this energy is restored with the practice of acupuncture or acupressure. The release of neurochemicals resulting from either acupuncture or acupressure stimulation is believed to occur, according to Traditional Chinese Medicine (TCM) practice. This practice has been identified through critical observations and testing over 4,000 years.
Pressure Right® received FDA 510(k) market clearance in 2011 for (Rx) use in surgical procedures to prevent the effects of postoperative nausea and vomiting following surgery. In a published trial by White, et al., the use of Pressure Right® in concert with antiemetic drug therapy (i.e., ondansetron and dexamethasone) was shown to substantially improve patient satisfaction with their management of postoperative nausea and vomiting (PONV) compared to antiemetic drugs alone. The risk-reduction benefit associated with Pressure Right® was very significant in “rescue medications” (i.e. 40% less) compared to the antiemetic group.
Additionally, in pre-clinical settings there is highly suggestive evidence the Pressure Right ® non-pharmacologic adjuvant approach can significantly help with the prevention of nausea and/or vomiting that are caused by chemotherapy medicine to treat cancer. Among the Pressure Right® use features are the patient’s ability to control the extent of prevention needed at a particular time. By pressing down on the device on both wrists for a few seconds, the patient can upgrade the prevention necessary in eliminating nausea and/or vomiting occurrences. Having this option available, the patients are basically in control of these debilitating effects while using Pressure Right®.
According to published clinical reporting this year, certain antiemetic agents were reviewed for cardiovascular side effects, which included 5-HT3 antagonists. In particular, QTc prolongation (heart rhythm disturbance) has become a clinical concern for chemotherapy patients. The extended use of corticosteroids, such as (dexamethasone), has also become a concern in chemotherapy use, which according to published drug information can weaken the immune system or cause arrhythmia, insomnia, headache side effects.
Moreover, according to the latest FDA-approved labeling, there are a few antiemetic agents, such as palonesetron and transdermal granisetron, which have not shown to induce or cause clinically significant QTc prolongation. However, these two agents may be cost-prohibitive for in-patient setting use.
The complimentary role of Pressure Right® without adverse effects, compared to antiemetic agents is paramount in developing satisfactory preventative patient care. In addition, the reliability and efficacy of the Pressure Right® antiemetic approach can provide a more inclusive backdrop in patient care as well as providing overall cost-efficiencies to hospital pharmacies.
Pressure Right® is a safe and effective low-cost antiemetic supplement shown to enhance clinical results with the lack of medication-related side effects. Patient satisfaction may not only be associated with better outcomes for the patient, but can be a reputational enhancement associated with the hospital.
When patient satisfaction improves it results in faster healing times and lowered re-admittance levels, thereby enabling greater cost controls.
Pressure Right® enables hospital pharmacies to bring down the cost aspects of antiemetic treatment, which can contribute to improving transitional patient care outcomes.
Contact Information:
Joseph DiLustro
Chairman & CEO
Pressure Point Inc.
Tel: (908) 601-8877
Email: therapeutics101@verizon.net
Website: pressurerightstrip.com
Help employers find you! Check out all the jobs and post your resume.
July 30, 2013 -- Hospital pharmacies across the US are recognizing the importance of improving patient transitional care in every facet of pharmacy administration. It is no longer a matter of dispensing drug medications, but to match products and services that create solutions, which can lead to improving overall patient satisfaction scores for hospitals. Pharmacies at hospitals are now searching for the best medical approach in order to provide a positive impact in patients’ lives during their hospital stay and after discharge.
An area of pharmaceutical administration that can be improved is antiemetic prophylactic drugs used to control nausea and vomiting symptoms associated with surgery and cancer procedures. Nausea, and to a lesser extent vomiting, continues to impact patients despite the introduction of many new antiemetics. The management issue of nausea following surgery or chemotherapy is still a major concern for hospitals and outpatient centers, since antiemetic drugs do not fully eliminate this debilitating side effect.
Understandably, the unresolved burden of nausea symptoms continues to be a negative influence on patients since this side effect occurrence produces severe quality of life implications, which can lead to a burdensome recovery.
In a collaborative effort to significantly improve transitional patient care associated with antiemetic prophylactic outcomes, a non-pharmacologic (noninvasive) therapy was clinically developed to supplement the primary objectives of antiemetic prophylactic therapy in effectively managing nausea and vomiting. Nausea and vomiting risks are substantially reduced with the adjuvant role of a 72-hour (Pressure Right®) antiemetic device. Its function clearly defines the difference in quality between antiemetics alone and Pressure Right® plus antiemetic therapy.
The proprietary design of the Pressure Right® (P6) wrist stimulation strips uses self-acupressure on the P6 stimulation point to control nausea and vomiting symptoms. The non-pharmacological scientific explanation is that these symptoms result from an imbalance in the flow of energy through the body and this energy is restored with the practice of acupuncture or acupressure. The release of neurochemicals resulting from either acupuncture or acupressure stimulation is believed to occur, according to Traditional Chinese Medicine (TCM) practice. This practice has been identified through critical observations and testing over 4,000 years.
Pressure Right® received FDA 510(k) market clearance in 2011 for (Rx) use in surgical procedures to prevent the effects of postoperative nausea and vomiting following surgery. In a published trial by White, et al., the use of Pressure Right® in concert with antiemetic drug therapy (i.e., ondansetron and dexamethasone) was shown to substantially improve patient satisfaction with their management of postoperative nausea and vomiting (PONV) compared to antiemetic drugs alone. The risk-reduction benefit associated with Pressure Right® was very significant in “rescue medications” (i.e. 40% less) compared to the antiemetic group.
Additionally, in pre-clinical settings there is highly suggestive evidence the Pressure Right ® non-pharmacologic adjuvant approach can significantly help with the prevention of nausea and/or vomiting that are caused by chemotherapy medicine to treat cancer. Among the Pressure Right® use features are the patient’s ability to control the extent of prevention needed at a particular time. By pressing down on the device on both wrists for a few seconds, the patient can upgrade the prevention necessary in eliminating nausea and/or vomiting occurrences. Having this option available, the patients are basically in control of these debilitating effects while using Pressure Right®.
According to published clinical reporting this year, certain antiemetic agents were reviewed for cardiovascular side effects, which included 5-HT3 antagonists. In particular, QTc prolongation (heart rhythm disturbance) has become a clinical concern for chemotherapy patients. The extended use of corticosteroids, such as (dexamethasone), has also become a concern in chemotherapy use, which according to published drug information can weaken the immune system or cause arrhythmia, insomnia, headache side effects.
Moreover, according to the latest FDA-approved labeling, there are a few antiemetic agents, such as palonesetron and transdermal granisetron, which have not shown to induce or cause clinically significant QTc prolongation. However, these two agents may be cost-prohibitive for in-patient setting use.
The complimentary role of Pressure Right® without adverse effects, compared to antiemetic agents is paramount in developing satisfactory preventative patient care. In addition, the reliability and efficacy of the Pressure Right® antiemetic approach can provide a more inclusive backdrop in patient care as well as providing overall cost-efficiencies to hospital pharmacies.
Pressure Right® is a safe and effective low-cost antiemetic supplement shown to enhance clinical results with the lack of medication-related side effects. Patient satisfaction may not only be associated with better outcomes for the patient, but can be a reputational enhancement associated with the hospital.
When patient satisfaction improves it results in faster healing times and lowered re-admittance levels, thereby enabling greater cost controls.
Pressure Right® enables hospital pharmacies to bring down the cost aspects of antiemetic treatment, which can contribute to improving transitional patient care outcomes.
Contact Information:
Joseph DiLustro
Chairman & CEO
Pressure Point Inc.
Tel: (908) 601-8877
Email: therapeutics101@verizon.net
Website: pressurerightstrip.com
Help employers find you! Check out all the jobs and post your resume.